Angle PLC Share Price: Live CLBX (AGL) Updates & Charts

If you’ve been watching Angle PLC over the past year, you’ve seen a familiar biotech story play out: bold growth forecasts, a rebranding effort, and a share price that keeps drifting lower. CelLBx Health (trading as CLBX on AIM) has now hit levels that weren’t seen since the dark days of 2022. The question is whether the analyst targets—some calling for dramatic upside—make this a genuine opportunity or just another trap for optimistic investors.

Exchange: London Stock Exchange AIM · Ticker: CLBX (formerly AGL) · Recent Event: Shares plunged on revenue warning · Director Activity: Buys and sells at 29p level · Company: CelLBx Health Plc (ex-Angle PLC)

Five data points tell the story of this AIM-listed biotech: the current price, the analyst targets, the financials, the cash runway, and the revenue warning that sent shares sharply lower.

The data below consolidates key metrics from LSE filings and financial platforms, illustrating how far CLBX has fallen from its 2025 peak.

What Stock Exchange is Angle PLC On?

Angle PLC—now rebranded as CelLBx Health Plc—trades on the London Stock Exchange’s AIM market, the London’s Alternative Investment Market designed for smaller, growth-oriented companies. The ticker changed from AGL to CLBX effective from market open on announcement day, making the stock more discoverable under its new identity.

Listing Details

CelLBx Health’s AIM listing places it among hundreds of earlier-stage UK companies seeking growth capital. AIM carries less regulatory scrutiny than the main market, which means lower compliance costs but also higher volatility and wider spreads for investors. The exchange’s own data feed provides official pricing and announcements.

Ticker Changes

The shift from AGL to CLBX wasn’t merely cosmetic. A ticker change signals a formal rebranding that affects how the company appears in broker platforms, news feeds, and investor portals. The new symbol better reflects the company’s current focus on pharmaceutical services, though the market’s reception to the announcement was muted at best.

The implication: AIM listing offers accessible entry for retail investors but demands higher due diligence, as the market sees frequent reversals among earlier-stage candidates.

Shares in the Guildford, England-based cancer research company declined 8.5% to 11.90 pence each on announcement day, reflecting investor focus on financial outlook rather than brand identity.

— Alliance News, reporting on LSE filing

Is Angle PLC a Good Buy?

Three-analyst consensus puts the median 12-month price target at 17.00 GBX, with estimates ranging from 4.00 to 30.00 GBX. The spread is enormous—spanning roughly 10× from low to high—which tells you that professional forecasters have wildly different views on what CelLBx Health is actually worth. Two analysts have issued Outperform ratings, with no current Buy, Hold, or Sell recommendations on record as of late October 2025.

Recent Performance

Trading at 0.90 GBX as of late April 2026, CLBX sits just 5.88% above its 52-week low of 0.85 GBX hit on April 13, 2026. The stock has cratered from its 52-week high of 17.45 GBX set on February 6, 2025—a decline exceeding 94% from that peak. This is a company that has been mercilessly sold by the market.

Director Ian F Griffiths bought and sold 37,500 shares at the 29p level, suggesting insiders see value at those levels—but the gap between 29p and the current sub-1p price is sobering.

— LSE director dealings disclosure

Pros and Cons

What is the Angle PLC Share Price Prediction?

Forecasts cluster around two scenarios. The bull case leans on analyst consensus: a median target of 17.00 GBX, implying 672.73% upside from the last observed price of 2.20 GBX. Fintel.io data shows a wider range of 4.04 to 31.50 GBX with an average target of 17.34 GBX, while one analyst projects a Strong Buy at 4.00 GBP.

Forecast Factors

Revenue growth is the primary driver cited by forecasters. Simply Wall St projects 45.1% annual revenue expansion, outpacing the broader UK healthcare market’s 4.7% growth. Earnings per share growth forecasts sit at 67.7% per annum—quadruple the Medical Equipment sector average of 17.7%.

Analyst Targets

The table below aggregates price targets from multiple platforms, showing the stark gap between current trading levels and analyst expectations.

The pattern: analyst targets suggest substantial upside exists—but only if CelLBx Health can execute on aggressive revenue growth while managing cash burn and avoiding dilutive fundraises.

What Happens to the Stock Price After a Merger?

CelLBx Health hasn’t completed a merger, but the recent rebrand from Angle PLC to CelLBx Health offers a case study in how identity changes affect share prices. The company’s shares declined 8.5% to 11.90 pence on the day of one key announcement, with investors responding more to the financial outlook than the name change itself.

Acquisition Effects

Historically, biotech acquisitions on AIM produce sharp initial pops as acquirers pay premiums, followed by extended consolidation periods. The pattern depends heavily on deal structure: all-stock deals tend to underperform cash deals in the months following announcement.

Angle Context

CelLBx Health did announce a placing to raise up to £2.06 million via 13,714,641 new shares. This dilutive move—filed officially with the London Stock Exchange—illustrates another form of shareholder event: the fundraise that stretches cash runway but dilutes existing holders. The market’s reaction to such announcements typically correlates with how the company communicates its burn rate and path to revenue.

The catch: every pound raised in new shares is a pound that doesn’t dilute existing shareholders, but every new share issued dilutes the pie. The asking price near 52-week lows signals urgency—or desperation.

Angle PLC Share Price Target and Future Outlook

For investors weighing in today, the bull case is mathematically compelling but operationally uncertain. Analyst consensus targets a 10-bagger from current levels—but the stock has spent most of the past year making a one-bagger in reverse. The path from £2.9m in 2024 revenue to profitability requires scaling the Parsortix diagnostic business faster than the market currently prices in.

Short-term Targets

The nearest catalyst is likely another placing or R&D tax credit receipt, both of which extend the cash runway without resolving the underlying profitability question. Director dealings at the 29p level—where Ian F Griffiths bought and sold 37,500 shares—suggest insiders see value at those levels, but the gap between 29p and the current sub-1p price is sobering.

Long-term Potential

Simply Wall St forecasts CLBX will grow earnings at 67.7% per annum—faster than most UK small-caps—but the -399.2% projected ROE means years of losses remain before breakeven. Clinical trials securing in 2025 represent the most concrete near-term catalyst, though the revenue warning issued suggests those trials haven’t yet moved the needle on commercial revenue.

Related reading: Pound to Euro Rate Today · Pounds to Australian Dollars

Frequently asked questions

For investors tracking this story, the bottom line is stark: CelLBx Health offers aggressive growth projections against a backdrop of persistent losses, constrained revenues, and a stock trading at the edge of its 52-week range. The analyst consensus says substantial upside exists—but the market has been pricing in the downside for months.